181 related articles for article (PubMed ID: 31533447)
1. The challenge of multiple cardiovascular risk factor control outside Western Europe: Findings from the International ChoLesterol management Practice Study.
Blom DJ; Santos RD; Daclin V; Mercier F; Ruiz AJ; Danchin N;
Eur J Prev Cardiol; 2020 Sep; 27(13):1403-1411. PubMed ID: 31533447
[TBL] [Abstract][Full Text] [Related]
2. Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International ChoLesterol management Practice Study (ICLPS).
Danchin N; Almahmeed W; Al-Rasadi K; Azuri J; Berrah A; Cuneo CA; Karpov Y; Kaul U; Kayıkçıoğlu M; Mitchenko O; Ruiz AJ; Aguilar Salinas CA; Santos RD; Mercier F; Blom D;
Eur J Prev Cardiol; 2018 Jul; 25(10):1087-1094. PubMed ID: 29771156
[TBL] [Abstract][Full Text] [Related]
3. Management of low-density lipoprotein cholesterol levels in South Africa: the International ChoLesterol management Practice Study (ICLPS).
Blom DJ; Raal F; Amod A; Naidoo P; Lai YE;
Cardiovasc J Afr; 2019 Jan/Feb 23; 30(1):15-23. PubMed ID: 30720848
[TBL] [Abstract][Full Text] [Related]
4. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
Reiner Z
Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
[TBL] [Abstract][Full Text] [Related]
5. Low-density lipoprotein cholesterol goal achievement in patients with familial hypercholesterolemia in countries outside Western Europe: The International ChoLesterol management Practice Study.
Blom DJ; Almahmeed W; Al-Rasadi K; Azuri J; Daclin V; Kayikcioglu M; Mercier F; Ruiz AJ; Santos RD;
J Clin Lipidol; 2019; 13(4):594-600. PubMed ID: 31208705
[TBL] [Abstract][Full Text] [Related]
6. Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: Insights from Italian general practice.
Arca M; Ansell D; Averna M; Fanelli F; Gorcyca K; Iorga ŞR; Maggioni AP; Paizis G; Tomic R; Catapano AL
Atherosclerosis; 2018 Apr; 271():120-127. PubMed ID: 29499359
[TBL] [Abstract][Full Text] [Related]
7. Lipid-lowering therapy and risk-based LDL-C goal attainment in Belgium: DA VINCI observational study.
van de Borne P; Peeters A; Janssens L; Leone A; Lemmens R; Verhaegen A; De Meulemeester M; Balthazar Y; Heijmans S; Calozet Y; Paquot N; Carlier S; Hemelsoet D; Bray S; Ray KK
Acta Cardiol; 2024 Feb; 79(1):20-29. PubMed ID: 35442151
[TBL] [Abstract][Full Text] [Related]
8. How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic.
Barkas F; Milionis H; Kostapanos MS; Mikhailidis DP; Elisaf M; Liberopoulos E
Curr Med Res Opin; 2015 Feb; 31(2):221-8. PubMed ID: 25418708
[TBL] [Abstract][Full Text] [Related]
9. Proportion of High-Risk/Very High-Risk Patients in Europe with Low-Density Lipoprotein Cholesterol at Target According to European Guidelines: A Systematic Review.
Bruckert E; Parhofer KG; Gonzalez-Juanatey JR; Nordestgaard B; Arca M; Giovas P; Ray K
Adv Ther; 2020 May; 37(5):1724-1736. PubMed ID: 32200537
[TBL] [Abstract][Full Text] [Related]
10. Achievement of LDL-C Targets Defined by ESC/EAS (2011) Guidelines in Risk-Stratified Korean Patients with Dyslipidemia Receiving Lipid-Modifying Treatments.
Yang YS; Lee SY; Kim JS; Choi KM; Lee KW; Lee SC; Cho JR; Oh SJ; Kim JH; Choi SH
Endocrinol Metab (Seoul); 2020 Jun; 35(2):367-376. PubMed ID: 32615721
[TBL] [Abstract][Full Text] [Related]
11. Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational study.
Vrablik M; Seifert B; Parkhomenko A; Banach M; Jóźwiak JJ; Kiss RG; Gaita D; Rašlová K; Zachlederova M; Bray S; Ray KK
Atherosclerosis; 2021 Oct; 334():66-75. PubMed ID: 34482090
[TBL] [Abstract][Full Text] [Related]
12. Non-achievement of LDL-cholesterol targets in patients with diabetes at very-high cardiovascular risk receiving statin treatment: Incidence and risk factors.
Breuker C; Clement F; Mura T; Macioce V; Castet-Nicolas A; Audurier Y; Boegner C; Morcrette E; Jalabert A; Villiet M; Avignon A; Sultan A
Int J Cardiol; 2018 Oct; 268():195-199. PubMed ID: 30041785
[TBL] [Abstract][Full Text] [Related]
13. The DA VINCI study: is Ireland achieving ESC/EAS guideline-directed LDL-C goals?
Offiah G; O'Connor C; Kennedy C; Gallagher J; O'Connor P; McAdam B; Ray KK; Schoonen M; Maher V
Ir J Med Sci; 2023 Jun; 192(3):1077-1084. PubMed ID: 35776266
[TBL] [Abstract][Full Text] [Related]
14. Healthcare resource utilization in patients on lipid-lowering therapies outside Western Europe and North America: findings of the cross-sectional observational International ChoLesterol management Practice Study (ICLPS).
Annemans L; Azuri J; Al-Rasadi K; Al-Zakwani I; Daclin V; Mercier F; Danchin N
Lipids Health Dis; 2020 Apr; 19(1):64. PubMed ID: 32264883
[TBL] [Abstract][Full Text] [Related]
15. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry.
Kotseva K; De Backer G; De Bacquer D; Rydén L; Hoes A; Grobbee D; Maggioni A; Marques-Vidal P; Jennings C; Abreu A; Aguiar C; Badariene J; Bruthans J; Castro Conde A; Cifkova R; Crowley J; Davletov K; Deckers J; De Smedt D; De Sutter J; Dilic M; Dolzhenko M; Dzerve V; Erglis A; Fras Z; Gaita D; Gotcheva N; Heuschmann P; Hasan-Ali H; Jankowski P; Lalic N; Lehto S; Lovic D; Mancas S; Mellbin L; Milicic D; Mirrakhimov E; Oganov R; Pogosova N; Reiner Z; Stöerk S; Tokgözoğlu L; Tsioufis C; Vulic D; Wood D;
Eur J Prev Cardiol; 2019 May; 26(8):824-835. PubMed ID: 30739508
[TBL] [Abstract][Full Text] [Related]
16. Lipid-modifying therapy and attainment of cholesterol goals in Hungary: the return on expenditure achieved for lipid therapy (REALITY) study.
Paragh G; Márk L; Zámolyi K; Pados G; Ofner P
Clin Drug Investig; 2007; 27(9):647-60. PubMed ID: 17705573
[TBL] [Abstract][Full Text] [Related]
17. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT
Circulation; 2019 Jun; 139(25):e1144-e1161. PubMed ID: 30586775
[TBL] [Abstract][Full Text] [Related]
18. Achievement of the ESC recommendations for secondary prevention of cardiovascular risk factors in high-risk patients with type 2 diabetes: A real-world national cohort analysis.
Salem AM; Harris D; Bray JJH; Obaid DR; Stephens JW; Halcox J
Int J Cardiol; 2023 Apr; 377():104-111. PubMed ID: 36764610
[TBL] [Abstract][Full Text] [Related]
19. Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany.
März W; Dippel FW; Theobald K; Gorcyca K; Iorga ŞR; Ansell D
Atherosclerosis; 2018 Jan; 268():99-107. PubMed ID: 29197254
[TBL] [Abstract][Full Text] [Related]
20. Current lipid lowering treatment and attainment of LDL targets recommended by ESC/EAS guidelines in very high-risk patients with established atherosclerotic cardiovascular disease: Insights from the START registry.
De Luca L; Arca M; Temporelli PL; Meessen J; Riccio C; Bonomo P; Colavita AR; Gabrielli D; Gulizia MM; Colivicchi F;
Int J Cardiol; 2020 Oct; 316():229-235. PubMed ID: 32470532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
